Vivos Therapeutics Inc. (VVOS) News

Vivos Therapeutics Inc. (VVOS): $3.74

-0.12 (-3.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter VVOS News Items

VVOS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VVOS News Highlights

  • VVOS's 30 day story count now stands at 8.
  • Over the past 26 days, the trend for VVOS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • WU, GOVX and GREE are the most mentioned tickers in articles about VVOS.

Latest VVOS News From Around the Web

Below are the latest news stories about Vivos Therapeutics Inc that investors may wish to consider to help them evaluate VVOS as an investment opportunity.

Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution

HIGHLANDS RANCH, Colo., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, and Candid Care Co. (“Candid”), a digital platform for oral healthcare, today announced a new collaboration that will seek to provide patients with a comprehensive, who

Yahoo | October 18, 2021

Vivos Therapeutics Inc.'s Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing treatment using the company’s FDA Class 1 registered Vivos Guide

Yahoo | October 13, 2021

Children in Latest Clinical Study Show Significant Reduction of Tooth Decay After Treatment with Vivos Guides

HIGHLANDS RANCH, Colo., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that results from a peer-reviewed, published study by an independent dentist found a significant reduction of tooth decay in p

Yahoo | October 13, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | September 29, 2021

16 Stocks Moving in Wednesday's Pre-Market Session

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) rose 29.7% to $5.42 in pre-market trading after the company reported the purchase of exclusive rights to PNP Therapeutics' development and commercialization of Gedeptin. Iterum Therapeutics plc (NASDAQ: ITRM) rose 25.5% to $0.6963 in pre-market trading. Iterum Therapeutics recently issued an update from the FDA Type A meeting regarding oral sulopenem. Greenidge Generation Holdings Inc.. (NASDAQ: GREE) rose 17.1% to $27.84 in pre-market trading after dropp

Yahoo | September 29, 2021

Vivos Therapeutics Inc. Forms Medical Consortium To Advance OSA Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University and Cecilia Wu of the University of Alberta, will collaborate to advance Vivos’

Yahoo | September 23, 2021

Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea

Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research and fostering increased physician-dental collaboration in the management of obstructive-sleep apneaHIGHLANDS RANCH, Colo., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from m

Yahoo | September 23, 2021

Vivos Therapeutics Inc. To Present At Benzinga Healthcare Small Cap Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm ET on Wednesday, Sept. 29, 2021. The event is scheduled to take place from Sept. 29-30, 2021. In

Yahoo | September 22, 2021

Vivos Therapeutics to Participate at the Benzinga Healthcare Small Cap Conference

Vivos management to present at 2:20 pm Eastern Time on September 29, 2021HIGHLANDS RANCH, Colo., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced that Vivos’ Chairman and Chief Executive Officer, Ki

Yahoo | September 22, 2021

Vivos Therapeutics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference

Vivos management to present at 7:00 am EDT on September 13, 2021 HIGHLANDS RANCH, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Chief Executive Officer, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Confe

Yahoo | September 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 10.0247 seconds.